$CC

Familiar Calderon Gerardo purchased $30K of CC

Familiar Calderon Gerardo (See Remarks) purchased 1,935 shares of Chemours Co (CC) at $15.53 on 2026-08-12.

Original reporting
SEC EDGAR · Familiar Calderon Gerardo
Published Aug 13, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

The newest disclosed fact is the officer’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note the insider buy, but there is no accompanying fundamental update in the text.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it also provides no context on motivation, prior trading history, or whether the insider has ongoing buy/sell patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-13 after-hours; transaction dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours insider Form 4 shows officer Familiar Calderon Gerardo bought 1,935 shares of CC on 2026-08-12 at $15.53.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically short-lived.

Evidence & confidence

Form 4 insider buys can be informative, but the article provides no earnings, guidance, deal, or regulatory development, and the transaction size is modest relative to company scale.

Market effects

No sector-level signal; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, compensation timing, or routine liquidity needs rather than a bullish view.

Key entities

  • Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • Familiar Calderon Gerardo

    Officer who purchased 1,935 shares of CC on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCHigh

Why is Chemours stock sliding today?

Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.

$CCMed

Mizuho downgrades Chemours stock rating on refrigerants delay

Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.

$CCHigh

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

$CCMedAI 8/10

Corporations Are Dodging Accountability for PFAS Contamination Around the Globe

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.